This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Qlaira Banner

Qlaira® (Estradiol valerate/dienogest)

Estradiol Valerate

E
2
V (oestradiol valerate) and E2 (oestradiol) are almost identical in terms of their pharmacokinetic and pharmacodynamic profile

Qlaira - MOA

E
2
V is the esterifield form of 17 ß-estradiol (E2)

Arrow Icon
Arrow Icon
Qlaira - MOA

It is rapidly absorbed and hydrolysed to E2 and valeric acid in the gastrointestinal mucosa

Qlaira Content Card
Qlaira® (Estradiol valerate/dienogest) | Dosing
Discover dosing of Qlaira®
PP-QLA-IE-0004-1, January 2026
arrow_forward
Qlaira Content Card
Qlaira® (Estradiol valerate/dienogest) | FAQs
Discover frequently asked questions about Qlaira®.
PP-QLA-IE-0003-1, January 2026
arrow_forward
Qlaira Content Card
Qlaira® (Estradiol valerate/dienogest)
Discover more about intended use of Qlaira®
PP-QLA-IE-0001-1, January 2026
arrow_forward

PP-QLA-IE-0002-1   |   January 2026

    • 1
      Guida M, et al. Int J Womens Health 2010;2:279–290.
    • 2
      Düsterberg B et al. Maturitas 1982;4:315–324.